TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01434264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Energy healing
Description: Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Energy healing
Description: Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair.
Study: NCT00736788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1704
Description: single dose oral suspension, 4 different dose levels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose oral suspension
Study: NCT01353144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin, 100 mg, qd x 8 weeks
Study: NCT02483689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre Incisional Local Anesthetic
Description: Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
Study: NCT00539240

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole 20mg, placebo dinner and bedtime
Description: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole 20 mg two times, Placebo at bedtime
Description: Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Description: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
Study: NCT02811822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Study: NCT02483689

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pre-Incisional Saline
Description: Patient will be given a max of 30 cc injected through a 22g needle to area of incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Closure Local Anesthetic
Description: Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post-Closure Saline
Description: Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
Study: NCT01463436

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
Study: NCT01458821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program - Tinnitus
Description: Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
Study: NCT02779829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number SR15-40-Z12-006.
Study: NCT03108209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photoderm Max lait SPF50+
Description: Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photoderm Max Stick SPF50+
Description: Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
Study: NCT04072185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
Study: NCT01810549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
Study: NCT02667379

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic skin testing
Description: 14 Skin prick tests on each volar forearm with cat dander samples.
Study: NCT00131664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet
Description: Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandia and Amaryl
Description: Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
Study: NCT00866268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low pressure suction drainage
Description: In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High pressure suction drainage
Description: In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
Study: NCT02243917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5083
Study: NCT01977339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Bupivacaine
Description: 10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 cc of 0.25% bupivacaine
Study: NCT01153841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™( GSK1024850A)
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, 3 doses
Study: NCT02811822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Study: NCT03282643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
Study: NCT03150537

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluviral influenza vaccine
Description: Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluviral influenza vaccine
Description: Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluviral influenza vaccine
Description: Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
Study: NCT01525823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807 (IGR-IR/IR Inhibitor)
Description: Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
Study: NCT04915638

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental intervention group with enriched cookies
Description: Enriched cookies containing a micronutrients formula (vitamins, minerals, antioxidants, and omega-3 fatty acids) each day (Monday to Friday).
Study: NCT02613741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle-based physical activity
Description: Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
Study: NCT04561687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast and nasal budesonide
Study: NCT03282643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: 0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
Study: NCT02093260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly.
Study: NCT04352816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiogram
Description: Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiogram
Description: Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiogram
Description: Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
Study: NCT00256750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (CsA)
Description: tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept LI (less intensive)
Description: solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept MI (more intensive)
Description: solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
Study: NCT04561687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine
Description: Azelastine and nasal budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: To all groups
Study: NCT01153841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular, 3 doses
Study: NCT01877824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-track training
Study: NCT01125878

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch composite B
Description: fiber mixture

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch composite C
Description: fiber mixture

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch composite D
Description: fiber mixture
Study: NCT00447967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
Study: NCT03980392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain intervention program
Description: Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain intervention program
Description: Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
Study: NCT03924804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's solution acetate
Description: Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's solution acetate
Description: Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's solution acetate
Description: Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
Study: NCT04561687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: To all groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: To all groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and nasal budesonide
Study: NCT02121275

Intervention type: DEVICE
Intervention: Ultrasound of the lungs
Description: Ultrasound examination of the lungs

Intervention type: DEVICE
Intervention: Electric impedance tomography
Description: Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
Study: NCT04386174

Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback
Description: Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback
Description: Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
Study: NCT04051463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil Ophthalmic Solution
Description: Netarsudil eye drops instilled once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops instilled once daily
Study: NCT04405440

Intervention type: BEHAVIORAL
Intervention: Behavioral avoidance task
Description: Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times

Intervention type: BEHAVIORAL
Intervention: Behavioral avoidance task
Description: Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
Study: NCT00508092

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthetic administration
Description: Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthetic administration
Description: Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight
Study: NCT04672135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REM0046127
Description: Oral solution: 100 mg/mL REM0046127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution with 0 mg/mL REM0046127
Study: NCT01335126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsion type artificial tear
Description: 2 types of artificial tears
Study: NCT03785184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: tablet; oral
Study: NCT01207817

Intervention type: OTHER
Intervention: Pupillometry
Description: Pupillometry readings will be taken at low, intermediate and high ambient light
Study: NCT02031432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Film-coated tablet; strengths: 200, 400, or 600 µg